We would love to hear your thoughts about our site and services, please take our survey here.
Interesting to note that a lot of buys have come in already in the first half hour of trading, far more than usual.
Will we see a PDMR purchase RNS tomorrow?
SYS FY results out today, finally giving a business update, but there is still an element of opacity I find frustrating.
On the surface (reduced cash, increased debt, FY EBITDA down 33% to £2m) it looks like there has been a much bigger organisational restructuring than previously stated. Without having access to the details of the restructuring and turnaround strategy, it grates a little that Heejae Chae refers to improving the company after years of stagnation because based purely on the FY numbers it looks like he has ousted the former CEO and turned a once-profitable company into a loss-making one.
However, there is a (fairly large) saving grace in the post-period highlights, announcing the signing of the second-largest order in Sys Group's history (£2.2m over 3 years). Does this suggest that Chae's opaque turnaround strategy is starting to bear fruit? He certainly has assembled an impressive set of advisors and industry contacts.
I have no idea how the market will interpret this.
Not sure what it's got to do with watching TV...?
Anyway, the "humilation" angle on Blinken's departure is apparently not accurate:
https://twitter.com/RushDoshi/status/1784627372160963014
But the need for the West to be independent of China & Russia still stands :)
This highlights the essential need for the West to be able to provide its own raw materials, energy and manufacturing to reduce the ability of bad actors like China and Russia to totally screw us over.
Biden's Govt is setting a strong agenda and backing it with a ton of money to get this done. The UK meanwhile has Russians in the House of Lords, a foreign secretary who refuses to disclose his close links with China, and we've lost the ability to manufacture steel...
That's not how shorts work. Shorting a stock means you have already sold it. To close out a short you need to BUY stock.
If shorts were closing, the share price will rise. Shorters closing doesn't suppress the price.
The 2 main drivers of daily share price fluctuations are fomo and fear.
There is no fomo with DKL, so the MMs can only go with fear, trying to get despairing PIs to sell up.
It's why all AIM shares drift down when there is no news.
Yes, there is a placing tomorrow, and 10000000000000000000 shares are going to be issued at a price of 0.0000000000000000001p.
The directors, who gave made 8 separate share purchases on the open market since the start of the year, will look like fools.
I'd better sell up now. Thanks for your concern.
(Accidentally posted too soon)
I presume the customer would just revert to the previous (pre-ITX) formulation, so wouldn't really take any time to change back.
Maybe the cost of old ingredients came down and used that as leverage against ITX?
I'm not holding my breath for the customer to come back, but I would like to see the lost low-margin profit replaced by higher margin beauty and hygiene sales.
I'm happy with the steady progress being made. Growing the international business and a progressive dividend policy.
Most PIs look at the numbers (revenue, dividend yield, etc...) and that biases their view of the company. They pay too much attention to the day-to-day or hour-to-hour movements of the share price, which is in turn influenced largely by other PIs.
But the biggest indicator of the company's value and future prospects is a section without bottom-line numbers attached to it. Have a re-read of this and then think why the company included it in the results:
• Value proposition for human challenge trials has been reinforced by recent positive outcomes:
• Pfizer's ABRYSVO™ became one of the first RSV vaccines to receive FDA approval in May 2023 having received Breakthrough Designation, following an PII HCT conducted by hVIVO
• At least two biotech clients received FDA Fast Track and/or Breakthrough Designation
And couple that with this statement:
• Upcoming move to the new state-of-the-art facility, which is largely funded by key clients, will increase revenue potential and position the Company for further margin improvements
If you know anything about biomedical research, you'll know how much time, money and other resources are spent on developing pipelines of medicines. And if hVivo are able to showcase that (so far) 3 clients have received Fast Track or Breakthrough Designations following data generated using hVivo's unique offering, then that is going to have huge ramifications for other biotech companies.
We can already see how important this is, in the second statement I highlighted. The new facility was *largely funded by key clients*. I challenge any PI here to show me another example of this happening.
There is a huge demand for hVivo's unique offering, by companies with very deep pockets.
Sure, sell out at 29p and try to time the market getting back in. Sure, complain that the dividend is 0.2p instead of 1p. But I guarantee that the IIs who were desperate to get in at 28p won't be reading today's RNS with the same focus that PIs are.
I added to my holding today in my ISA with some of my new allowance.
The risk/reward at this price is too good to pass up.
I am a patient investor, I'm looking for big returns over the medium to long-term, so I don't mind if the noisy herd aren't here.
As per today's RNS, 4 PDMRs exercised options for shares and sold sufficient amount to cover their tax liabilities.
This was not a trivial amount: 184,000 shares.
So, apart from going ex-div, this might be one reason why there has been share price weakness over the past few days. In light of this, I would expect the downtrend has ended (ceteris paribus...) and it's unlikely to go below 200p.